Protein N-myristoylation: functions and mechanisms in control of innate immunity

Bin Wang1, Tong Dai1, Wenhuan Sun1, Yujun Wei2, Jiang Ren3, Long Zhang4, Mengdi Zhang4 and Fangfang Zhou3

INTRODUCTION
In eukaryotes, most proteins must undergo alternative splicing and extensive modifications, such as protein glycosylation, phosphorylation, or lipidation, after synthesis to reach their active and functional forms. Indeed, attachment of lipid groups is vital for proteins to achieve their final native structure and to allow intracellular transport for them to reach the appropriate cellular localization.1–3 Protein lipidation can be divided into four major types: N-myristoylation, S-palmitoylation, prenylation, and glycosylphosphatidylinositol anchor conjugation.4

N-myristoylation is a ubiquitous protein lipid modification that occurs cotranslationally in eukaryotes and involves attachment of myristic acid to the N-terminal glycine (Gly) of a wide range of substrate proteins.5,6 Representative N-Gly-myristoylated proteins for which experimental evidence is available are summarized in Table 1. Although N-myristoylation is an evolutionarily conserved host defense mechanism,7–9 it is not in prokaryotes.10–12 Lower eukaryotes have only one isoform of NMT, whereas most mammals express two isozymes.13 In humans, NMT isoforms, NMT1 and NMT2, are expressed in most tissues and are essential for cell survival, regulation of immune responses, and HIV-1 infection.20–26

Innate immunity is an evolutionarily conserved host defense mechanism.7,27 In contrast to adaptive immunity, the innate immune system immediately responds to pathogens but does not provide long-lasting immunity to the host.28 The immediate pathogen response of innate immunity is achieved through multiple germline-encoded pattern-recognition receptors (PRRs) that recognize various pathogen-associated molecular patterns (PAMPs), including DNA and RNA from bacteria and viruses, and danger-associated molecular patterns (DAMPs).30–37 Downstream signaling cascades, including adaptors, kinases, and transcription factors, are activated via upstream signaling following the recognition of common pathogen constituents by PRRs. This leads to expression of antimicrobial genes and cytokines, including proinflammatory cytokines, chemokines, and type I interferons (IFNs), to recruit immune cells to infected sites and eliminate pathogens.38–41 Recent studies showing modulation of the TLR4 pathway by N-myristoylation,42 demyristoylation-induced innate immunosuppression during Shigella flexneri infection,43 and involvement of N-myristoylation in HIV-1 pathogenesis44 have resulted in increasing attention on the interplay between protein N-myristoylation and innate immunity.

In this review, we illustrate the basic principles of protein N-myristoylation and summarize recent important findings on the relationship between protein N-myristoylation and innate immunity. It might enable us to clarify the pathogenesis of certain infectious diseases and better harness protein N-myristoylation for new therapeutics.

**Keywords:** N-myristoylation; Innate immunity; Myristoyl switches; Infection; TLR4; Viral assembly

**Cellular & Molecular Immunology** (2021) 18:878–888; https://doi.org/10.1038/s41423-021-00663-2

1Institute of Biology and Medical Science, Soochow University, Suzhou, Jiangsu 215123, China; 2Anhui Anlong Gene Technology Co., Ltd, Hefei 230041, China; 3The Eighth Affiliated Hospital, Sun Yat-sen University, Guangdong 518033, China and 4MOE Key Laboratory of Biosystems Homeostasis & Protection and Innovation Center for Cell Signaling Network, Life Sciences Institute, Zhejiang University, Hangzhou, Zhejiang 310058, China

Correspondence: Fangfang Zhou (zhoufangfang@suda.edu.cn)

These authors contributed equally: Bin Wang, Tong Dai, Wenhuan Sun, Yujun Wei

Received: 26 October 2020 Accepted: 18 February 2021
Publish online: 17 March 2021

© The Author(s), under exclusive licence to CSI and USTC 2021
mechanisms underlying innate immune modulation by N-myristoylation. We also describe the vital role of myristoylation in viral assembly, intracellular host interactions, and spread during HIV-1 infection. Although the field of protein myristoylation is new and rapidly growing, this modification undoubtedly plays essential roles in human physiology as well as in important pathological conditions. Thus, there is a need for an updated overview of recent advances in the field to maximize our knowledge on protein N-myristoylation into therapeutic discovery.

THE BIOLOGY AND MECHANISMS OF PROTEIN MYRISTOYLETION

N-myristoyltransferases (NMTs)

Both cotranslational and posttranslational protein myristoylation require the enzymes NMT and myristoyl-CoA to catalyze the transfer of a myristate group to a Gly residue of a protein. NMT belongs to the GCN5-related N-acetyltransferase protein family. Various studies have reported that NMT is a ubiquitous enzyme in eukaryotes, as it can be found in some lower eukaryotic organisms (e.g., Caenorhabditis elegans, Entamoeba histolytica, and Giardia lamblia), various land plants (e.g., Arabidopsis thaliana, Oryza sativa, and Lycopersicon esculentum), and almost all mammals. Conversely, prokaryotes do not possess NMTs, and these enzymes appear to have arisen as eukaryotes evolved from the archael common ancestor to the eukaryotic common ancestor. Some mammalian species (e.g., humans and mice) possess the two isoforms NMT1 and NMT2; lower eukaryotes only have one isoform. However, they all share a conserved sequence that constitutes the catalytic domain.

Human NMT1 (hNMT1) and NMT2 (hNMT2), which share only 76%–77% protein sequence identity, contain 496 and 498 amino acids, respectively (Fig. 2A). In addition, although hNMT2 is only phosphorylated at Ser38, hNMT1 can be phosphorylated at Ser31, Ser47, and Ser83 (Fig. 2A). hNMT1 and hNMT2 show a similar distribution in different organs, but expression of hNMT1 in the healthy heart, gut, kidney, liver, and other organs is higher than that of hNMT2. Studies on NMT1 and NMT2 enzyme kinetics and functions have found different substrate affinities for the two enzymes, with NMT1 playing more substantial roles in embryonic development, apoptosis, and cell proliferation. Overall, these findings suggest that NMT1 may exert major functions and require more complex regulation than NMT2.

The N-terminal amino acid sequences of NMT substrates are similar. In addition to containing a Gly at position one of the N-terminal ends, several myristoylated proteins require a Ser/Thr residue at the fifth position of the N-terminus (G-X-X-X-S/T-X-X-X-). NMTs also catalyze the myristoylation of proteins following the Bi–Bi mechanism (Fig. 1A). After recognizing myristoyl-CoA, NMT binds myristoyl-CoA to form the NMT-myristoyl-CoA complex, which triggers exposure of the substrate-binding pocket of the enzyme. Subsequently, NMT recognizes and binds to the N-terminal sequence signal of the protein. Finally, NMT catalyzes protein N-myristoylation and releases products; NMT simultaneously returns to its initial conformation, in which the substrate-binding pocket is hidden.

Myristoyl switches

As mentioned earlier, promoting the binding of proteins to the cell membrane is one of the most important functions of protein myristoylation. Hydrophobic insertion of the myristoyl chain into the lipid bilayer is necessary but not sufficient for the membrane binding of myristoylated proteins. A fundamental question in the field is as follows: how do cells or organisms regulate stable binding or reversible dissociation between myristoylated proteins?

### Table 1. A representative of N-Gly-myristoylated proteins with experimental evidence

| Protein types | Protein | Refs. |
|--------------|---------|-------|
| Viral proteins | Gag (Lentiviruses) | 21,174 |
| | Nef (Retroviruses, Poxviruses) | 175 |
| | v-src (Rous sarcoma virus) | 176 |
| | VP2 coat protein (Polyomaviruses) | 177 |
| | VP4 coat protein (The viruses of Picornaviridae) | 178 |
| | Large surface antigen (HBV) | 179 |
| | Major outer capsid protein μ1 (Ortho- and arenaviruses) | 180 |
| | A16L (VV) late protein (The viruses of Poxviridae) | 181 |
| Tyrosine kinases | Abl, Blk, Fgr, Fyn, Hick, Lyn, Src, Yes | 176,182 |
| Ca²⁺-binding EF-hand proteins | Recoverin, neuronal calcium sensor, visinin, frequenin, neurocalcin, hippocalcin | 183,184 |
| GTP-binding proteins | Calcinurin B phosphatase subunit, p22 | 185,186 |
| | Guanylate cyclase activators | 187 |
| S/T-kinases | ADP ribosylation factors (ARF) and ARF-like (ARL) | 133 |
| | Rab5-related (Ara6) | 188 |
| | G-protein alpha subunits | 189,190 |
| | S/T-kinases | 191 |
| | cAMP-dependent kinases | 192,193 |
| | cGMP-dependent kinase II | 194 |
| | Ca²⁺/calmodulin-dependent kinases | 195 |
| Other | Myristoylated alanine-rich carboxy-kinase substrate (MARCKS) | 69 |
| | Endothelial nitric oxide synthase (eNOS) | 196 |
| | TRIF-related adaptor molecule (TRAM) | 42 |
| | Fibroblast growth factor receptor substrate 2α (FRS2α) | 77 |
and lipid bilayer membranes? Actually, with the help of a second signal, including phosphates, positively charged ions, or another modification, the myristoylated protein can be stably attached to or reversibly dissociate from the cell membrane. During this process, the myristoyl motif plays a "switch" role. Three main myristoyl switch models have been proposed: a myristoyl-electrostatic switch, myristoyl-ligand switch, and myristoyl-palmitoyl switch (Fig. 2B). The myristoyl-electrostatic switch refers to enhancing or preventing the binding of the myristoylated protein to the lipid membrane by affecting the protein's surface charge. One of the best examples of an electrostatic-mediated myristoyl switch protein is myristoylated alanine-rich C kinase substrate (MARCKS). Following phosphorylation by protein kinase C (PKC), the phosphate motif reduces the positive charge on the surface of MARCKS, resulting in its dissociation from the membrane to the cytosol. In a few cases, the myristoyl moiety will be sequestered in a hydrophobic pocket following myristoylation. Conformational alterations triggered by specific ligands in such proteins will expose the myristoyl moiety, a mechanism known as the myristoyl-ligand switch. For instance, the myristoyl group of GDP-inactive ARF1 is sequestered but liberated by GTP exchange for membrane binding and signaling. Similar to the myristoyl group, the palmitoyl group, which is a 16-carbon fatty chain, can promote attachment of proteins to the cell membrane. Regarding the myristoyl-palmitoyl switch, some proteins require both a myristoyl group and palmitoyl group to target the membrane. For example, Barylko et al. demonstrated that stable membrane localization and kinase activity of fibroblast growth factor receptor substrate 2α (FRS2α) are mediated by myristoylation and palmitoylation and proved that N-myristoylation-negative mutants of FRS2α do not incorporate palmitate and therefore cannot attach to the plasma membrane.

Lys myristoylation
Protein N-myristoylation is thought to occur exclusively at the N-terminal Gly residue. However, protein N-myristoylation also occurs at the epsilon amino groups of internal lysines of proteins. Recent studies have revealed that the transfer of myristate to the N-terminal ε-amino groups of lysine side chains is also catalyzed by NMT, expanding the range of known myristoylation substrates. Moreover, when α- and ε-amino groups are both available on the same peptide, NMT preferentially catalyzes Gly myristoylation rather than Lys myristoylation. Interestingly, in contrast to irreversible Gly myristoylation, several acyl hydrolases

Fig. 1 The molecular mechanism of protein N-myristoylation catalyzed by N-myristoyltransferase (NMT). A Cotranslational protein N-myristoylation and the Bi–Bi mechanism. After removal of the initiator methionine by methionine aminopeptidase 2 (MetAP2), NMT catalyzes the delivery of myristic acid from myristoyl-CoA to the N-terminal glycine residue of a protein. The reaction catalyzed by NMT follows an ordered Bi–Bi mechanism. After the recognition and binding of the fatty acid chain of myristoyl-CoA, the substrate-binding pocket is exposed. Subsequently, NMT recognizes and binds to the N-terminal sequence signal of the protein. Finally, NMT catalyzes protein N-myristoylation and releases products. Simultaneously, NMT returns to its previous conformation, in which the substrate-binding pocket is hidden. B Posttranslational protein N-myristoylation during apoptosis. P21-activated kinase 2 (PAK2) is cleaved by caspase 3 to produce caspase-truncated PAK2 (ctPAK2), which has a newly exposed glycine residue at the N-terminus. Then, NMT catalyzes the covalent attachment of myristic acid to the glycine residue of ctPAK2. Posttranslationally myristoylated ctPAK2 translocates to subcellular membrane compartments to induce apoptosis.
targeting Lys myristoylation have recently been found, including Sirtuin1/2/3/6 (SIRT1/2/3/6) and histone deacetylase 8/11 (HDAC8/11), rendering Lys myristoylation a reversible modification. This suggests that Lys myristoylation, as with other reversible modifications (e.g., palmitoylation, phosphorylation), may be intimately involved in regulating various signaling pathways. Overall, this reversible protein N-myristoylation mechanism provides an exciting field for the exploration of more functions of N-myristoylated proteins in human health and diseases.

FUNCTIONS OF PROTEIN MYRISTOYLATION IN HUMAN INNATE IMMUNE REGULATION AND RESPONSES

Innate immunity

The human immune system is composed of innate immunity and adaptive immunity. T and B cells are the main adaptive immune cells, and they have several specific and unique receptors. Numerous B lymphocytes constitute multitudinous B-cell receptors (BCRs), thus increasing the probability of encountering an antigen that binds to a given BCR. The process of clonal expansion of B cells does, however, require 3–5 days, which may allow for enough time for the pathogen to cause damage. Compared with adaptive immunity, innate immunity can be activated quickly after pathogen invasion. Indeed, it is the body’s first line of defense against pathogen invasion until a sufficient number of antibodies are produced by B cells.

When pathogens invade vertebrates, innate lymphocytes, such as macrophages and dendritic cells, recognize and bind to PAMPs or DAMPs through PRRs, inducing expression of proinflammatory factors, IFNs, and hundreds of interferon-stimulated genes. These effectors help the host to rapidly remove invading pathogens. PAMPs are highly conserved molecular structures unique to a group of specific microbial pathogens and their products. The best-known examples of PAMPs include single- or double-stranded RNA, viral DNA, and lipopolysaccharide (LPS) of gram-negative bacteria. As PAMPs are not produced by the host, they are regarded by innate immune cells as molecular characteristics of infection. A variety of PRRs have been discovered thus far. PRRs can be divided into two categories according to their cellular localization: the first type of PRRs localize to the cytoplasm of most cells, such as RIG-I-like receptors and cyclic GMP-AMP synthase; the second type of PRRs localize to the cell membrane, such as Toll-like receptors (TLRs).

TLRs are mainly expressed on the plasma membrane of DCs, macrophages, neutrophils, and lymphocytes. Early studies of antifungal responses in Drosophila melanogaster were critical to the discovery of the Toll protein. Subsequently, the human homolog of Drosophila Toll was identified as TLR4. TLRs detect microbial cell surface components; for example, TLR4 detects LPS, TLR5 senses flagellin, and TLRs 1, 2, and 6 recognize bacterial lipoproteins. Other TLRs also detect nucleic acids, such as double-stranded RNA (TLR3), single-stranded RNA (TLR7 and 8), unmethylated CpG containing single-stranded DNA (TLR9), and bacterial ribosomal RNA (TLR13). After recognizing ligands, TLRs recruit adaptor molecules to induce expression of inflammatory factors or IFNs. This ensemble of inflammatory factors and IFNs promote inflammation and host defense.

Fig. 2 Human NMTs and the three main myristoyl switch models. A Comparison of the functional domains and phosphorylated residue positions between human NMT1 (hNMT1) and human NMT2 (hNMT2). Both hNMT1 and hNMT2 have three similar myristoyl-CoA binding sites. hNMT2 is only phosphorylated at the Ser38 residue, whereas hNMT1 can be phosphorylated at Ser31, Ser47, and Ser83. B Schematic illustration showing the three main myristoyl switch models: myristoyl-electrostatic switch, myristoyl-ligand switch, and myristoyl-palmitoyl switch. In the myristoyl-electrostatic switch model, when MARCKS is phosphorylated by PKC, the phosphate motif reduces the positive charge on its surface, which results in its dissociation from the membrane to the cytosol. In the myristoyl-ligand switch model, the myristoyl group of recoverin is exposed following the binding of two Ca2+ ions by EF-hand motifs, which induces recoverin binding to the membrane; without Ca2+, the myristoyl moiety is hidden in the hydrophobic pocket. In the myristoyl-palmitoyl switch model, FRS2α requires conjugation to both a myristoyl group and a palmitoyl group for membrane targeting and kinase activity stimulation.
Myristoylation regulates TRIF-related adaptor molecule (TRAM) and TLR4-dependent inflammatory responses

TLR4-dependent inflammatory responses are activated by LPS, a complex glycolipid that represents a major constituent of the gram-negative bacterial cell wall. Upon binding LPS, TLR4 dimerizes and recruits all four types of Toll/IL-1 resistance (TIR) domain-containing adaptor molecules: myeloid differentiation factor 88 (MyD88), MyD88 adapter-like, TIR domain-containing adaptor-inducing IFN-β (TRIF), and TRIF-related adaptor molecule (TRAM). Among these TIR domain-containing adaptor molecules, TRAM functions exclusively in the TLR4 pathway. Recently, Rowe reported that TRAM-mediated regulation of TLR4 signal transduction depends on myristoylation. TRAM colocalizes with TLR4 on the plasma membrane through its N-terminal myristoyl group. Upon detection of dimerized TLR4, TRAM dissociates from TLR4 and the membrane to interact with TRIF and further activate the NF-κB and IRF3 pathways. TRAM relies on two main myristoyl-dependent mechanisms to dissociate from the membrane and regulate TLR4 signaling (Fig. 3). The first mechanism is the myristoyl-electrostatic switch of TRAM. A recent study demonstrated that TRAM is phosphorylated by PKCe during TLR4 signaling. Following LPS stimulation, TRAM is transiently phosphorylated by PKCe on Ser-16 near its N-terminus, and this phosphorylation event adjacent to the myristoyl group reduces the electrostatic interaction between multiple residues and the phospholipid head groups, leading to dissociation of TRAM from the membrane. This process is not only essential for the activation of IRF3 and NF-κB but also, more importantly, constitutes a negative feedback mechanism for the TLR4 signaling pathway, avoiding excessive production of inflammatory cytokines. Notably, TRAM also undergoes tyrosine phosphorylation at Tyr167 within its TIR domain following LPS stimulation. However, Tyr167 phosphorylation mainly serves to activate downstream signals and is not involved in the myristoyl-electrostatic switch of TRAM.

The other mechanism by which myristoylated TRAM regulates TLR4 signaling involves the myristate-binding protein heme oxygenase-2 (HO-2) (Fig. 3). Heme oxygenase (HO) catalyzes degradation of heme to generate biliverdin. There are two main isoforms of HO: inducible HO-1 and constitutively expressed HO-2. Constitutively expressed HO-2 can be found in all cell types, whereas HO-1 is only highly expressed following oxidative stress or induction by inflammatory stimuli. Increasing evidence indicates that HO-2 is vital for the timely shutdown of inflammatory responses. In contrast to normal mice, HO-2-knockout mice show a defect in wound healing and severe inflammation. The LPS-TLR4 inflammatory response in mouse cerebral vascular endothelial cells is inhibited by overexpression of HO-2, though it is enhanced by RNAi-mediated knockdown of HO-2. In an exciting new study, Zhu et al. identified HO-2 as a myristate-binding protein that binds to the myristoyl group of TRAM to negatively regulate the LPS-TLR4 pathway. Activation of TLR4 signaling boosts expression of inflammatory cytokines and promotes expression and activation of HO-2. In turn, HO-2 binds to the myristoyl group and inhibits the function of TRAM. Structural analysis has demonstrated that the myristoyl group is inserted almost completely into a deep hydrophobic pocket of HO-2. Moreover, depleting HO-2 or blocking access to its myristate pocket enhances hyperresponsive LPS-TLR4 signaling. This work not only illustrates the regulatory mechanism of HO-2 in the LPS-TLR4 pathway but also raises some interesting questions. For example, why is constitutively expressed HO-2, but not inducible HO-1, a myristate-binding protein? Is TRAM trapped within HO-2 released, and how does this occur? If it is not released, is it degraded by the proteasome or delivered to another membrane? These important questions remain to be answered.

Fig. 3 The role of myristoylation in regulating TRIF-related adaptor molecule (TRAM) during LPS-induced TLR4 inflammatory responses. TRAM is myristoylated and anchored to the plasma membrane. After LPS stimulation, TLR4 dimerizes to recruit the TIR domains of cytoplasmic adaptor molecules, including Mal, TRAM, MyD88, and TRIF, which further activate NF-κB and IRF3 signaling to produce the proinflammatory cytokines IFN-β. Notably, following interaction with TLR4, TRAM is transiently phosphorylated by PKCe on Ser-16, which is near its N-terminus. This phosphorylation event adjacent to the myristoyl group reduces the electrostatic interaction between multiple residues and phospholipid head groups, leading to TRAM dissociation from the membrane. This process is not only essential for the activation of IRF3 and NF-κB but also, more importantly, constitutes a negative feedback mechanism of the TLR4 signaling pathway, avoiding excessive production of inflammatory cytokines. Notably, TRAM also undergoes tyrosine phosphorylation at Tyr167 within its TIR domain following LPS stimulation. However, Tyr167 phosphorylation mainly serves to activate downstream signals and is not involved in the myristoyl-electrostatic switch of TRAM.
Demystroylation-induced innate immunosuppression in Shigella flexneri infection

To escape host innate and adaptive immune system supervision, microbial pathogens produce virulence proteins (also called effectors) to hijack host cellular signal transduction.128 Bacteria employ specialized needle-like delivery systems to secrete effectors into the host cell, including the type III and IV secretion systems (T3SS and T4SS, respectively).129 Effectors are translocated through either the T3SS or T4SS, whereas DNA is only transferred through the T4SS.130 The effectors are inactive in the bacterium but become activated by eukaryotic activators in host cells following delivery.129 Activated effectors manipulate signal transduction pathways to induce immunosuppression, thereby potentiating their replication.129

For a long time, protein N-terminal Gly myristoylation has been regarded as an irreversible, stable modification. However, in a recent study, Burnaevskiy et al. revealed that invasion plasmid antigen J (IpaJ), a T3SS effector protein secreted by Shigella flexneri, is a demystroylating enzyme that hydrolyzes the myristoyl group from the N-terminal Gly of human ARF1.43 Functionally, ARF1 couples to and promotes the GTPase cycle of ARF6.134 Nevertheless, ARF1-5 localizes to the Golgi and recruit target proteins, thereby triggering transport vesicle formation.135 Viruses lack the N-myristoylated proteins in vitro, including c-Src, MARCKS, hVPS15, and GRASP65,43 suggesting that IpaJ might also target multiple myristoylated proteins during Shigella infection. However, whole-cell myristoylome profiling to identify physiological substrates of IpaJ during Shigella infection has revealed that IpaJ targets only some members of the ARF family (ARF1-5 but not ARF6) and members of the related ARF-like (ARL) family.132 Further analysis showed that to cleave the substrate, IpaJ not only requires the presence of myristoyl but also must interact with structural elements and residues utilized by ARF effector proteins.132 In addition, IpaJ displays selectivity toward Golgi-associated ARFs.129 ARF1-5 localizes to the Golgi and functions to regulate trafficking between the Golgi and endoplasmic reticulum.133 ARF6, however, resides at the plasma membrane and is the only member of the ARF family that is not demystroylated by IpaJ during Shigella infection.132 A recent study may explain why IpaJ cannot demystroylate ARF6. Unlike other proteins that are myristoylated at N-terminal Gly residues, ARF6 is myristoylated at an N-terminal ε-lysine residue by NMTs.134 As IpaJ can only cleave the peptide bond between N-myristoylated Gly and the N-terminal second amino acid residue,135 ARF6 is not efficiently cleaved by IpaJ. Interestingly, the myristoyl group of ARF6 can be removed by the NAD⁺-dependent deacylase SIRT2. Moreover, SIRT2 binds preferentially to GDP-bound ARF6, while NMTs prefer to bind GTP-bound ARF6. Therefore, the Lys-myristoylation–demystroylation cycle can couple to and promote the GTPase cycle of ARF6.134 Nevertheless, whether bacterial Lys demystroylases exist and the relationship between Lys myristoylation and innate immunity remain unknown. Although an initial framework has been formed from these findings to explore the multiple functions of protein N-myristoylation in human innate immunity, additional studies in this field are necessary to develop more effective and safer antimicrobial drugs.

Myristoylation and HIV-1 pathogenesis

In addition to its indispensable roles in protein stability, cellular signal transduction, and targeting of proteins to plasma membrane systems, myristoylation is vital for viral invasion, assembly, intracellular host interactions, and budding.135 Viruses lack the
enzymes NMT, which is required for N-myristoylation; therefore, their proteins are myristoylated by eukaryotic NMTs. Apart from a few exceptions, 136,137 the Gag proteins of nearly all retroviruses are cotranslationally myristoylated at the amino-terminal Gly of the matrix domain (MA). 138,139 Pharmacological inhibition of NMTs or mutation of the Gag MA domain to prevent myristoylation suppresses the assembly and budding of HIV-1 in host cells. 140,141 Thus, N-myristoylation of Gag proteins is vital for HIV-1 replication. During the late stages of infection, Gag, which consists of the four domains p17 matrix (MA), p24 capsid (CA), p7 nucleocapsid (NC), and p6 starts to be synthesized in host cells. 142 (Fig. 5A). However, the myristoyl group of newly synthesized Gag is partially (~60%) sequestered in the MA domain, preventing the interaction between Gag and membranes. 143 In the late stages of infection, the myristate groups of Gag need to be exposed to be able to bind to the plasma membrane and promote assembly. A recent study showed that Gag multimerization triggers a conformational switch from the myristoyl-sequestered state to the myristoyl-exposed state. 144 The interaction between the viral RNA template and the NC domain promotes Gag multimerization, thereby exposing their myristoyl moieties. 145 and Gag oligomers will then be able to bind to the plasma membrane via their myristoyl groups and direct particle assembly. During or shortly after budding, the viral protease is activated to cleave Gag, which liberates the mature MA, CA, and NC proteins and the unstructured peptides p2, p1, and p6 for viral maturation. 146 In addition to TRAM, HO-2, a newly discovered cellular myristate-binding protein, can specifically bind to the myristoyl moiety of HIV-1 Gag, thereby inhibiting the association between HIV-1 Gag and the membrane. 147 Inhibition of HO-2 myristate-binding activity by mutation or with the use of a noncleavable substrate analog significantly enhances the production of HIV-1. 148 These findings indicate that negative regulation of HIV-1 Gag by HO-2 may be a host cell innate defense mechanism during virus infection. Regardless, it is unclear how intracellular HO-2 is activated and binding specificity is achieved during HIV-1 infection. Answering these important questions is necessary to develop new anti-HIV-1 drugs.

A previous study described a protein that negatively regulates virus replication: Nef. 149 Interestingly, subsequent research found that the Nef protein can promote virus replication and infection. 150,151,152 After being N-terminal Gly-myristoylated by host NMTs, HIV-1 Nef is found in the cytoplasm and plasma membrane. 148,149 HIV-1 Nef promotes HIV-1 invasion and spread by several mechanisms (Fig. 5A): (1) by activating CD4+ T lymphocytes, Nef promotes viral spread among CD4+ T lymphocytes; 150 (2) to prevent premature apoptosis of infected cells, Nef inhibits the activity of ASK1; 151,152 and (3) Nef downregulates major histocompatibility complex class I (MHC-I), which is essential for cytotoxic T lymphocyte (CTL) recognition, to prevent the death of HIV-1-infected cells by CTLs. 153 Moreover, Nef is involved in the downregulation of CD4+ receptors from the cell surface. 154 NMT1 has been shown to preferentially associate with HIV-1 Nef; moreover, the myristoyl group of Nef is essential for its activity, and mutation of the N-terminal myristoylation site on Nef cripples its activities. Overall, the myristoylation of Nef may play a vital role in HIV-1 activities.

Nef is also critical for the spread of HIV-1. Following recognition and binding of HIV-1 by a DC-specific receptor (DC-SIGN), DCs deliver viral particles to target cells without becoming effectively infected. Nonetheless, DCs may be infected by viral particles, further promoting the efficient spread of HIV to other uninfected DCs and T cells by Nef (Fig. 5B). 155 In addition to DCs, Nef facilitates the productive transmission of HIV-1 infection from macrophages to T cells. 156,157 Nef induces the production of the CC chemokines macrophage inflammatory protein 1α and 1β as well as other soluble factors (soluble CD23 and soluble ICAM) in macrophages to recruit T cells and facilitate productive transmission of HIV-1 infection (Fig. 5B). However, it is unclear whether the myristoyl moiety of Nef is essential for the induction of these chemokines and factors. Moreover, the role of myristoylation in the Nef-mediated spread of HIV-1 infection remains to be fully elucidated.

CONCLUSIONS AND PERSPECTIVES

Over the past decade, N-myristoylation has become an attractive area of protein modification research. The exciting evidence obtained from
structural, genetic, and biomedical studies has unquestionably revealed that protein N-myristoylation plays nonnegligible functions in broad biological processes, such as apoptosis, hematopoiesis, carcinogenesis, immune response, and viral infections.\textsuperscript{26,158,159} Despite some breakthroughs, an increasing number of unknown areas have emerged, including protein Lys myristoylation, demyristoylation, and novel cellular myristate-binding proteins.

Protein N-myristoylation is well established as Gly myristoylation, but the new area of Lys myristoylation remains mostly unexplored. Although a large number of Gly-myristoylated proteins involved in various biological processes have been identified, Lys-myristoylated proteins have rarely been found. As Lys myristoylation is reversible, several important proteins in various signaling pathways may undergo this modification. With the improvement of mass spectrometry, not only will more Lys-myristoylated proteins be identified, but our knowledge about the functions of protein myristoylation in cellular activities will also increase. Furthermore, both Gly myristoylation and Lys myristoylation are catalyzed by NMTs, but the catalytic mechanism and substrate specificity of NMTs require further investigation.

Recent discoveries regarding the regulation of Gly myristoylation during infection have revealed IpA\textsubscript{J} as the first Gly-demystoylating enzyme.\textsuperscript{15,122} These findings point to novel directions with regard to the dynamic regulation of Gly myristoylation and pathogen interference of host protein myristoylation. However, our understanding of the regulation of Gly myristoylation is still in its infancy, and it remains to be determined whether other microbial proteases cleave Gly myristoylation as a pathogenic mechanism. A better understanding of the dynamic cellular regulation of Gly myristoylation by pathogens would deepen our knowledge of the mechanisms of pathogen invasion. In addition, evidence has identified HO-2 as a negative regulator of virus replication and demonstrated that the LPS-TLR4 signaling pathway is involved in binding of N-myristoylated Gag and TRAM.\textsuperscript{122} Nevertheless, how the binding specificity and activities of HO-2 are regulated in a timely manner is still largely unknown. More in-depth studies on the regulation of HO-2 may reveal new perspectives on how the host defends itself against pathogen invasion.

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a novel coronavirus, has caused the coronavirus disease 2019 (COVID-19) global pandemic.\textsuperscript{109} Following the identification of the first case in China, many studies have been conducted to understand this novel virus. SARS-CoV-2 has four main structural proteins: membrane (M), envelope (E), nucleocapsid (N), and spike (S).\textsuperscript{166} Among them, the S protein is the most important for the virus to successfully invade cells. S proteins decorate the surface of the virus, and viral entry into cells is initiated when these proteins bind to the host angiotensin-converting enzyme 2 receptor.\textsuperscript{162,167} Accordingly, many antibody therapies in development target the S proteins.\textsuperscript{162–172} However, there are few studies on other therapeutic targets of SARS-CoV-2. Although there is no known protein motif for Gly myristoylation of coronavirus proteins,\textsuperscript{172} the recently discovered lysine myristoylation protein indicates potential SARS-CoV-2 protein myristoylation. This is limited to speculation, and there is no report confirming it. Therefore, it is necessary to determine the relationship between the pathogenesis of SARS-CoV-2 and protein N-myristoylation, which may constitute a target in the development of COVID-19 therapeutic drugs.

Finally, as protein N-myristoylation is crucial for virus assembly and spread, host NMT may be an exciting target for developing antiviral drugs.

ACKNOWLEDGEMENTS

We would like to apologize to those researchers whose related work we were not able to cite in this review. This work was supported by a special program from the Ministry of Science and Technology of China (2016YFA0020000 to L.Z.), the Chinese National Natural Science Funds (U20A0393, 82041009, 31925013, 31671457, and 91753139 to L.Z.; 31871405 and 31571460 to F.Z.), Jiangsu National Science Foundation (BK20180043 and 19KJA550003 to F.Z.), the Zhejiang Natural Science Fund (LJ19C070001 to L.Z.), the Key Project of University Natural Science Foundation of Jiangsu Province (19KJA550003), and a project funded by the Priority Academic Program Development of Jiangsu Higher Education Institutions.

AUTHOR CONTRIBUTIONS

B.W., T.D., W.S., and Y.W. contributed equally to this work. B.W., T.D., W.S., and Y.W. conceived and drafted the manuscript. W.B. prepared the figures. M.Z. and R.J. discussed the concepts of the manuscript. F.Z. and L.Z. provided valuable discussion and revised the manuscript.

ADDITIONAL INFORMATION

Competing interests: The authors declare no competing interests.

REFERENCES

1. Casey, P. Protein lipidation in cell signaling. Science 268, 221–225 (1995).
2. Chen, B., Sun, Y., Niu, J., Jarugumilli, G. K. & Wu, X. Protein lipidation in cell signaling and diseases: function, regulation, and therapeutic opportunities. Cell Chem. Biol. 25, 817–831 (2018).
3. Nadolski, M. J. & Linder, M. E. Protein lipidation. FEBS J. 274, 5202–5210 (2007).
4. Jiang, H. et al. Protein lipidation: occurrence, mechanisms, biological functions, and enabling technologies. Chem. Rev. 118, 919–988 (2018).
5. Boutin, J. A. Myristoylation. Cell. Signal. 9, 15–35 (1997).
6. Farazi, T. A., Waksman, G. & Gordon, J. I. The biology and enzymology of protein N-myristoylation. J. Biol. Chem. 276, 39501–39504 (2001).
7. Zha, J., Weiler, S., Oh, K. J., Wei, M. C. & Korsmeyer, S. J. Posttranslational N-myristoylation of BID as a molecular switch for targeting mitochondria and apoptosis. Science 290, 1761–1765 (2000).
8. Martin, D. D. O., Beauchamp, E. & Berthiaume, L. G. Post-translational myristoylation: fat matters in cellular life and death. Biochimie 93, 18–31 (2011).
9. Adam, R. M. et al. Cholesterol sensitivity of endogenous and myristoylated Akt. J. Biol. Chem. 285, 13561–13568 (2010).
10. Schwartsser, U. et al. Myristoylation of the dual-specificity phosphatase c-Jun N-terminal kinase (JNK) stimulatory phosphatase 1 is necessary for its activation of JNK signaling and apoptosis. FEBS J. 277, 2463–2473 (2010).
11. Tan, Y. W., Hong, W. J. & Chu, J. J. H. Inhibition of enterovirus VP4 myristoylation is a potential antiviral strategy for hand, foot and mouth disease. Antivir. Res. 133, 191–195 (2016).
12. Wright, M. H., Heal, W. P., Mann, D. J. & Tate, E. W. Protein myristoylation in health and disease. J. Chem. Biol. 3, 19–35 (2010).
13. McChinnery, R. A. J. Protein Targeting Protocols (ed. Clegg, R. A.) 211–225 (Humana Press, 1998).
14. Maurer-Stroh, S. et al. MYRibase: analysis of genome-wide glycylation myristoylation enlarges the functional spectrum of eukaryotic myristoylated proteins. Genome Biol. 5, R21 (2004).
15. Timms, R. T. et al. A glycline-specific N-degron pathway mediates the quality control of protein N-myristoylation. Science 365, eaaw4912 (2019).
16. Ames, J. B., Tanaka, T., Stryer, L. & Ikura, M. Portrait of a myristoyl switch protein.Curr. Opin. Struct. Biol. 6, 432–438 (1996).
17. Towler, D. A. et al. Purification and characterization of yeast myristoyl CoA protein N-myristoyltransferase. Proc. Natl Acad. Sci. 84, 2708–2712 (1987).
18. Meinnel, T., Dian, C. & Giglione, C. Myristoylation, an ancient protein modification mirroring eukaryogenesis and evolution. Trends Biochem. Sci. 45, 619–632 (2020).
19. Ducker, C. E., Upson, J. J., French, K. J. & Smith, C. D. Two N-myristoyltransferase isozymes play unique roles in protein myristoylation, proliferation, and apoptosis. Mol. Cancer Res. 3, 463–476 (2005).
20. Bouamr, F., Scarlata, S. & Carter, C. Role of myristylation in HIV-1 Gag assembly. Biochemistry 42, 6408–6417 (2003).
21. Reihl, M. D. A myristoyl switch regulates membrane binding of HIV-1 Gag. Proc. Natl Acad. Sci. U. S. A. 101, 417–418 (2004).
22. Li, H., Dou, J., Ding, L. & Spearman, P. Myristoylation is required for human immunodeficiency virus type 1 Gag-Gag multimerization in mammalian cells. J. Virol. 81, 12899–12910 (2007).
Protein N-myristoylation: functions and mechanisms in control of innate immunity

B Wang et al.
88. Dambuza, I. M. & Brown, G. D. C-type lectins in immunity: recent developments. Curr. Opin. Immunol. 32, 21–27 (2015).
89. Gay, N. & Keith, F. J. Drosophila Toll and IL-1 receptor. Nature 351, 355–356 (1991).
90. Steward, R. Dorsal, an embryonic polarity gene in Drosophila, is homologous to the vertebrate proto-oncogene, c-reln. Science 238, 692–694 (1987).
91. Schneider, D. S., Hudson, K. L., Lin, T. Y. & Anderson, K. V. Dominant and recessive mutations define functional domains of Toll, a transmembrane protein required for dorsal-ventral polarity in the Drosophila embryo. Genes Dev. 5, 797–807 (1991).
92. Medzhitov, R., Preston-Hurlburt, P. & Janeway, C. A. Jr A human homologue of the Drosophila Toll protein signals activation of adaptive immunity. Nature 388, 394–397 (1997).
93. Brubaker, S. W., Bonham, K. S., Zanoni, I. & Kagan, J. C. Innate immune pattern recognition: a cell biological perspective. Annu. Rev. Immunol. 30, 257–290 (2013).
94. Poltorak, A. et al. Defective LPS signaling in C3H/HeJ and C57Bl/10ScCr mice: mutations in Tlr4 gene. Science 282, 2085–2088 (1998).
95. Gewirtz, A. T., Navas, T. A., Lyons, S., Godowski, P. J. & Madara, J. L. Cutting edge: TRIF-related adapter molecule that participates in Toll-like receptor 3-mediated interferon-γ production. J. Immunol. 174, 1529–1533 (2005).
96. Hayashi, F. et al. The innate immune response to bacterial RNA. Science 298, 253–257 (2002).
97. Kang, J. Y. et al. Recognition of lipopeptide patterns by Toll-like receptor 2-Toll-like receptor 6 heterodimer. Science 313, 849–853 (2006).
98. Takeuchi, O. et al. Differential roles of TLR2 and TLR4 in recognition of gram-negative bacteria. Cell 104, 451–457 (2001).
99. Heil, F. et al. Species-specific and strain-positive bacterial cell wall components. Immunity 11, 443–451 (1999).
100. Takeuchi, O. et al. Discrimination of bacterial lipoproteins by Toll-like receptor 6. Int. Immunol. 13, 933–940 (2001).
101. Takeuchi, O. et al. Cutting edge: role of Toll-like receptor 1 in mediating immune response to microbial lipoproteins. J. Immunol. 169, 10–14 (2002).
102. Alexopoulos, L., Holt, A. C., Medzhitov, R. & Flavel, B. A. Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3. Nature 413, 732–738 (2001).
103. Diebold, S. S., Kaisho, T., Hemmi, H., Akira, S. & Reis e Sousa, C. Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA. Science 303, 1529–1531 (2004).
104. Greulich, W. et al. TLR7 is a sensor of RNA virus nucleocapsid proteins. J. Virol. 82, 8452–8458 (2008).
105. Muzzio, M., Ni, J., Fong, P. & Dixit, V. M. IRAK (Pelle) family member IRAK-2 and MyD88 as proximal mediators of IL-1 signaling. Science 278, 1612–1615 (1997).
106. Fitzgerald, K. A. et al. Mal (MyD88-adaptor-like) is required for Toll-like receptor-4 signal transduction. Nature 413, 78–83 (2001).
107. Hong, T., Barton, G. M., Flavel, R. A. & Medzhitov, R. The adaptor molecule TRIF provides signaling specificity for Toll-like receptor-3 ligands. Proc. Natl Acad. Sci. U. S. A. 102, 420–433 (2005).
108. Yamamoto, M. et al. Cutting edge: a novel Toll/IL-1 receptor domain-containing adaptor that preferentially activates the IFN-beta promoter in the Toll-like receptor signaling. J. Immunol. 169, 6668–6672 (2002).
109. Yamamoto, M. et al. Role of adaptor TRIF in the MyD88-independent Toll-like receptor signaling pathway. Science 301, 640–643 (2003).
110. Vogel, S. N. & Fenton, M. Toll-like receptor 4 signalling: new perspectives on a complex signal-transduction problem. Biochem. Soc. Trans. 31, 664–668 (2003).
111. Muzzio, M., Ni, J., Fong, P. & Dixit, V. M. IRAK (Pelle) family member IRAK-2 and MyD88 as proximal mediators of IL-1 signaling. Science 278, 1612–1615 (1997).
112. Whiteman, G. M., Wille, A. K., Yang, X., Brown, H. L. & Medzhitov, R. Phosphorylation of MyD88 by IKKalpha and IKKbeta at serines 172 and 181 contributes to Toll-like receptor-mediated NF-kappaB activation. J. Immunol. 174, 3313–3318 (2005).
113. Indraccolo, S. & Medzhitov, R. The molecular mechanism of MyD88-dependent toll-like receptor signaling. Annu. Rev. Immunol. 34, 565–597 (2016).
114. Noguchi, M., Yoshida, T. & Kikuchi, G. Species specificity of TLR4-mediated NF-κB activation in macrophages. J. Immunol. 188, 1908–1915 (2007).
115. Noguchi, M., Yoshida, T. & Kikuchi, G. NF-kappaB activation in mouse macrophage cell lines induced by lipopolysaccharide: role of TLR4 and MyD88. Biochem. J. 387, 417–424 (2005).
116. Huai, W. et al. Phosphatase PTPN4 preferentially inhibits TRIF-dependent TLR4 pathway by dephosphorylating TRAM. J. Immunol. 194, 4458–4465 (2015).
117. Palmiter, R. D., Gagnon, J., Vogt, V. M., Ripley, S. & Eisenman, R. N. The NH2-terminal domain of TRAF6 forms an intrinsic protein-protein interaction domain required for the p53-inducing activity of TRIF. Nat. Immunol. 5, 1043–1055 (2004).
118. Miller, M. D., Feinberg, M. B. & Greene, W. C. The HIV-1 nef gene acts as a positive viral infectivity factor. Trends Microbiol. 2, 294–298 (1994).
119. Miller, M. D., Warmerdam, M. T., Gaston, L., Greene, W. C. & Feinberg, M. B. The human immunodeficiency virus-1 nef gene product: a positive factor for viral infection and replication in primary lymphocytes and macrophages. J. Exp. Med. 179, 101–113 (1994).
Protein N-myristoylation: functions and mechanisms in control of innate...

B Wang et al.

148. Fackler, O. T. et al. Association of human immunodeficiency virus Nef protein with actin is myristoylation dependent and influences its subcellular localization. *Eur. J. Biochem.* **247**, 843–851 (1997).

149. Bentham, M., Mazaleyrat, S. & Harris, M. Role of myristoylation and N-terminal basic residues in membrane association of the human immunodeficiency virus type 1 Nef protein. *J. Gen. Virol.* **87**, 563–571 (2006).

150. Skowronska, J., Parks, D. & Mariani, R. Altered T cell activation and development in transgenic mice expressing the HIV-1 nef gene. *EMBO J.* **12**, 703–713 (1993).

151. Badley, A. D. et al. Macrophage-dependent apoptosis of CD4+ T lymphocytes from HIV-infected individuals is mediated by Fasl and tumor necrosis factor. *J. Exp. Med.* **185**, 55–64 (1997).

152. Geleziunis, R., Xu, W., Takeda, K., Ichijo, H. & Greene, W. C. HIV-1 Nef inhibits AKT1-dependent death signalling providing a potential mechanism for protecting the infected host cell. *Nature* **410**, 834–838 (2001).

153. Wu, A. et al. Genome composition and divergence of the novel coronavirus associated with actin is myristoylation dependent and in...